Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

• Responders had a distinct fraction of molecular subtypes compared to non-responders, highlighting treatment effectiveness.
• In the study, 5 patients were classified per consensus, with 4 patients under TCGA classification for treatment responses.
• There were no neuro-endocrine subtypes found in the patient cohort, indicating specific limitations in molecular diversity.
• Treatment dynamics involving ipilimumab and nivolumab demonstrate the importance of biomarker analysis in therapy outcomes.